Michael Taylor

Michael Taylor, PhD has over 30 years of work experience in the field of toxicology and preclinical drug development. Michael began their career at Syntex as a Toxicologist I and eventually became a Toxicologist II. Michael then worked at Roche Bioscience, where they served as a Principal Research Scientist and later as the Department Head of Toxicology. Following their time at Roche Bioscience, Dr. Taylor joined DURECT Corporation as the Executive Director of NonClinical R&D and later became the Vice President of NonClinical R&D. Michael then held the role of Senior Director of Toxicology and Pharmacokinetics at PDL BioPharma. Dr. Taylor went on to become the Vice President of Preclinical Development at Alexza Pharmaceuticals and later served as the Vice President of Preclinical Drug Safety at Limerick BioPharma. In 2010, they became an Advisor at SPARK Advisory Board at Stanford University Medical School. Recently, Dr. Taylor joined Alumis as the Vice President of Toxicology in 2021. Throughout their career, they have also founded and served as the President of NonClinical Safety Assessment, providing a range of consultation services in the field of nonclinical/preclinical safety assessment.

Michael Taylor earned their Ph.D. in Toxicology from Utah State University, completing their studies from 1985 to 1988.